Click here for the CME evaluation / post-test

Activity Index
Click on the titles below to view the presentations.

Wednesday, October 3, 2007

Session I: Etiologic pathogenesis of melanoma
Moderator: Boris C. Bastian, MD

Opening address: Molecular analysis of melanoma progression
Dorothea Becker, PhD

Roles for vitamin D in melanoma pathogenesis
Julia Newton-Bishop, MD

Session II: Current and emerging diagnostic and imaging technologies
Moderator: John M. Kirkwood, MD

Ultrasonographic lymph node assessment
John F. Thompson, MD

Advances in optical imaging of the skin
Peter T.C. So, PhD

Keynote lecture: The clinical utility of molecular genetics for melanoma diagnosis, classification,
and therapy stratification
Boris C. Bastian, MD

Session III: Advances in surgery and staging
Moderator: John F. Thompson, MD

Serum and tumor profiling of human melanoma
Aleksandar Sekulic, MD, PhD

The role of tumor lymphangiogenesis in melanoma nodal metastasis
Soheil S. Dadras, MD, PhD

The evolving role of surgery for melanoma: Metastasectomy and beyond
Jeffrey E. Gershenwald, MD

Session IV: Adjuvant therapy
Moderator: Helen Gogas, MD

Molecular HLA typing and outcome
Helen Gogas, MD

Autoimmunity and other markers of risk and response to interferon in ECOG studies
John M. Kirkwood, MD

Predicting outcome in EORTC interferon studies
Alexander M.M. Eggermont, MD, PhD

Case presentation:
Should micrometastatic disease in the sentinel node receive adjuvant therapy?
Moderator: Vernon K. Sondak, MD

Expert Panel: Alexander M.M. Eggermont, MD, PhD, Helen Gogas, MD,
and John M. Kirkwood, MD


Thursday, October 4, 2007

Session V: Metastatic disease: Contemporary and investigational targeted agents
Moderator: Alexander M.M. Eggermont, MD, PhD

What have we learned after 30 years of cooperative group trials?
Vernon K. Sondak, MD

Targeting the MAP kinase pathway: RAF and MEK inhibition
Keith T. Flaherty, MD

Targeting the PI3 kinase/AKT pathway: mTOR inhibition
Kim A. Margolin, MD

HDAC inhibitors: Overcoming resistance
Adil I. Daud, MD

New classes of therapeutics for melanoma
Steven J. O’Day, MD

Session VI: Regulation of immunity: Keys to melanoma therapy
Moderator: Thomas Gajewski, MD, PhD

The dichotomous influence of the immune system in melanoma
Thomas Gajewski, MD, PhD

Selective stimulation of T-cell subsets with antibody-cytokine complexes
Charles D. Surh, PhD

Overcoming STAT3 mediated negative immunoregulation
Hua Yu, PhD

Session VII: Melanoma vaccines
Moderator: Vernon K. Sondak, MD

Experimental role of MHC and KIR: The role of NK and NK-Tcells in immune response and effector function
Christine S. Falk, PhD

New insights and questions about the use of adjuvant and cytokines for optimizing immune responses to multipeptide melanoma vaccines
Craig L. Slingluff, Jr., MD

Advances in vaccination
Esteban Celis, MD, PhD

Therapeutic potential of genetically engineered vaccines
Lisa H. Butterfield, PhD

Click here for the CME evaluation / post-test